Please Note: The Tufts Health Public Plans program goes live on September 12, 2022, for dates of service on or after October 1, 2022.
We’re entering a new era of precision medicine, where treatments can be targeted and disease risks identified for individuals based on their genetic makeup. Today, there are more than 65,000 molecular diagnostic tests (sometimes called genetic tests) available, and the number is growing. Navigating this rapidly advancing area of medicine can be a challenge for your practice and your patients.
Point32Health (the parent company of Harvard Pilgrim Health Care and Tufts Health Plan) has partnered with AIM Specialty Health® (AIM) to help ensure quality care while reducing costs associated with care that’s not evidence-based. This site will help you understand how the Point32Health Molecular Diagnostics Management program works, and the benefits for both you and your patients.